Key result
Liraglutide was evaluated for its effects on cardiovascular events in patients with type 2 diabetes mellitus stratified by coronary, cerebrovascular, and peripheral vascular territories.
Why the study?
Does liraglutide reduce cardiovascular events in patients with type 2 diabetes mellitus and polyvascular disease?
Does liraglutide reduce cardiovascular events in patients with type 2 diabetes mellitus and polyvascular disease?
Answers are grounded in this paper and cite their sources.
Liraglutide effects in polyvascular T2DM remain uncertain; leaves open differential benefits by vascular territory.
2] In this post hoc analysis of LEADER, we evaluated the effects of liraglutide stratified by a number of atherosclerotic vascular territories (coronary, cerebrovascular, and peripheral).
No takes yet. Share an insight, caveat, or question.
Verma et al. (2018) studied this question. Liraglutide was evaluated for its effects on cardiovascular events in patients with type 2 diabetes mellitus stratified by coronary, cerebrovascular, and peripheral vascular territories.
Synapse has enriched 10 related papers. Consider them for comparative context: